AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company focused on developing botulinum toxin-based therapeutics that entered the public markets through a de-SPAC business combination with Priveterra Acquisition Corp. The company filed a Form 10-Q/A, an amendment to a previously submitted quarterly report, on March 3, 2022, with accession number 0001104659-22-029710, reflecting updated disclosures during the period surrounding its merger process. AEON operates in the biotechnology and life sciences sector, and its SPAC transaction places it among the wave of biopharma companies that pursued blank-check vehicles as a path to public listing. Sign up for full data on SpacDesk to access AEON's complete filing history, deal timelines, and analytics.